Anti-LI-Cadherin-17 CDH17-Rabbit Monoclonal Antibody

Overview

This product is an anti-CDH17 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFFC-3; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, IP (as provided in the source record). Boster Bio Anti-LI-Cadherin-17 CDH17-Rabbit Monoclonal Antibody catalog # M06389. Tested in WB, IHC, IP applications. This antibody reacts with Human.

Key elements and design rationale

• Target: CDH17 (Type II inositol 3,4-bisphosphate 4-phosphatase).
• Antibody format: Monoclonal; clone AFFC-3; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

CDH17 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4- trisphosphate and inositol 1,4-bisphosphate. Reported cellular localization context: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Tissue expression notes (as provided): Widely expressed with highest levels occurring in the skeletal muscle and heart. .

Research relevance and current trends

• Research context keywords from the source record include: Cadherins,Cell Adhesion,Cytoskeleton/ECM,Signal Transduction.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunoprecipitation (IP): enrich target complexes for downstream immunoblot or interaction analyses.

Workflow ideas (metafield): Validate CDH17 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect CDH17 expression by Western blot in cell or tissue lysates, Detect CDH17 in FFPE tissue sections by immunohistochemistry, Enrich CDH17 by immunoprecipitation from lysates for downstream analysis

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 72 kDa; calculated MW: 104738 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 72 kDa
• Cellular localization (provided): Cytoplasm, cytoskeleton, microtubule organizing center, centrosome .
• Tissue details (provided): Widely expressed with highest levels occurring in the skeletal muscle and heart. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.